More treatment options are needed for patients with ITP1,2
Current treatment goals in ITP are to stop active bleeding and reduce the risk of further bleeding. Response rates for ITP treatments vary widely from 18% to 80% as measured by improved platelet counts. Some currently available treatments may also be associated with unfavorable side effect profiles and dosing regimens or offer a limited duration of response.
“I worry about my treatment failing at some point. I worry about the long-term health effects of the drugs that I’m taking.”
Tracey, US, patient with ITP
“Despite advances in treatment options over the years, some patients remain refractory to existing therapies and durable remission remains elusive.”
David Kuter, MD, Director of Clinical Hematology at Massachusetts General Hospital
Ongoing research aims to better address the multiple dimensions of ITP by targeting the underlying pathology of the disease.3,4
1. Cooper N, Ghanima W. Immune thrombocytopenia. N Engl J Med. 2019;381(10):945-955. 2. Bussel J, Arnold DM, Grossbard E, et al. Fostamatinib for the treatment of adult persistent and chronic immune thrombocytopenia: results of two phase 3, randomized, placebo-controlled trials. Am J Hematol. 2018;93(7):921-930. 3. Audia S, Bonnotte B. Emerging therapies in immune thrombocytopenia. J Clin Med. 2021;10(5):1004-1023. 4. Mingot-Castellano ME, Bastida JM, Caballero-Navarro G, et al. Novel therapies to address unmet needs in ITP. Pharmaceuticals (Basel). 2022;15(7):779.